Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $486

Wells Fargo analyst Benjamin Burnett has maintained an Equal-Weight rating on United Therapeutics (NASDAQ: UTHR) and raised the price target from $466 to $486.